Our vision

Advanced clinical data science

Phesi provides comprehensive clinical development analytical products and services for biopharmaceutical companies around the world. Our integrated offerings cover the entire clinical development process — from development planning and indication assessment to protocol evaluation, site selection, and trial implementation management.

Transform clinical development design, planning and delivery through the use of dynamically updated, real-world data analytics and insights

Automate analysis throughout the program, protocol and trial design, recruitment and management processes using our patented AI platform

Improve program efficiency and reduce costs across all phases of development and all therapeutic areas

Partner with trial sponsors to remove barriers to conducting effective clinical trials, and to get novel therapies to patients faster


Accelerate drug development and commercialization

To ensure precise trial protocol design and flawless execution across all phases of development and indications (including rare diseases), enabling life sciences companies to deliver novel therapies to patients faster and at a reduced cost.

our team

Leadership team

Gen Li PHD, MBA President & Founder
Jonathan Peachey Chief Operations Officer
Paul Chew MD Chief Medical Officer
Guoqiang Wu Chief Information Officer
read more
our clients

Customer experience

Phesi is on the frontiers of defining clinical development as a science, performing systematic analysis of the clinical trial, clinical protocol, and clinical site space to form hypotheses about what will work and what will not. Through observation and experiment you are applying those learnings to inform new clinical programs or save old ones. Phesi is more than the sum of its parts and the value is in the integration.


Every global R&D leader should know about this and should be testing it within their portfolio.

senior director, clinical operations tekada

Phesi worked with us to show that a particular adaptive trial design would give the best performance. The result was a significantly quicker and cheaper devel­opment time on this priority asset.

senior director, clinical operations tekada